biolay
interferometri
bli
realtim
labelfre
technolog
greatli
contribut
advanc
vaccin
research
develop
bli
octet
platform
offer
highthroughput
eas
use
reliabl
high
precis
analysi
compar
common
label
techniqu
mani
differ
strategi
use
immobil
pathogen
host
molecul
bli
biosensor
realtim
kinet
affin
analysi
quantif
highthroughput
titer
strategi
use
multipl
applic
shed
light
onto
structur
function
aspect
molecul
play
pathogenhost
interact
also
provid
crucial
inform
achiev
protect
review
summar
key
bli
strategi
use
human
vaccin
research
develop
realtim
labelfre
rtlf
technolog
greatli
contribut
research
develop
product
vaccin
recent
year
biosensor
technolog
base
surfac
plasmon
reson
spr
surfac
plasmon
reson
imag
spri
biolay
interferometri
bli
proven
practic
effect
monitor
molecular
interact
bind
event
monitor
realtim
without
requir
supplementari
costli
label
rtlf
biosensor
techniqu
power
use
character
molecular
interact
stage
vaccin
product
develop
extens
inform
avail
multipl
platform
spr
review
articl
focus
use
bli
technolog
divers
platform
use
variou
stage
vaccin
research
develop
use
bli
technolog
increas
rapidli
past
decad
trend
predict
continu
technolog
continu
gain
widespread
accept
diversifi
applic
base
bli
optic
analyt
techniqu
measur
interfer
pattern
white
light
reflect
two
surfac
tip
dispos
biosensor
proprietari
refer
surfac
constant
sampl
chemistri
surfac
variabl
monitor
real
time
interact
two
differ
molecul
oneth
ligandimmobil
onto
biosensor
surfac
otherth
analytei
kept
solut
biosensor
coat
coval
noncoval
link
differ
biolog
molecul
allow
kinet
quantit
measur
molecul
bound
tip
molecular
interact
inform
like
kinet
rate
constant
affin
bind
constant
specif
molecul
quantit
main
character
inform
deduct
bli
platform
inform
necessari
character
studi
molecular
interact
import
complement
technolog
provid
function
inform
molecul
typic
bli
bind
kinet
experi
assay
begin
initi
baselin
use
assay
buffer
follow
ligand
molecul
immobil
surfac
biosensor
load
follow
anoth
baselin
step
associ
analyt
bind
step
final
dissoci
presenc
buffer
bind
respons
measur
report
real
time
form
sensorgram
trace
fit
use
specifi
algorithm
base
known
bind
model
kinet
measur
fast
interact
occur
depict
relationship
associ
rate
constant
k
dissoci
rate
constant
k
constant
express
k
k
affin
measur
strong
interact
depict
bind
reach
equilibrium
usual
refer
affin
constant
k
dissoci
equilibrium
constant
express
molar
concentr
analyt
requir
occupi
surfac
ligand
site
equilibrium
constant
readili
calcul
softwar
data
analysi
quantit
experi
molecul
bound
biosensor
quantifi
relat
set
standard
similar
characterist
softwar
algorithm
base
known
curv
equat
deliv
quantit
cv
inform
tradit
assay
like
equilibrium
bind
assay
endpoint
assay
cumbersom
fail
provid
complet
inform
interact
tradit
technolog
like
enzymelink
immunosorb
assay
elisa
high
perform
liquid
chromatographi
hplc
nativepag
gel
capillari
electrophoresi
singl
radial
immunodiffus
srid
encumb
drawback
includ
long
assay
time
extens
handson
label
low
throughput
case
addit
techniqu
elisa
srid
exhibit
high
variabl
result
lower
accuraci
poor
precis
biolay
interferometri
bli
combin
highthroughput
characterist
plate
format
improv
precis
reproduc
eas
use
higher
throughput
bli
technolog
combin
robot
platform
biosensor
technolog
like
spr
requir
extens
instrument
mainten
buffersampl
treatment
microfluid
mainten
add
time
cost
oper
accur
label
free
kinet
quantit
molecul
fundament
vaccin
studi
allow
scientist
better
understand
mechan
molecular
interact
without
need
label
molecul
time
consum
may
interfer
molecul
biolog
activ
global
vaccin
market
ever
demand
popul
grow
microb
adapt
increas
thu
press
need
technolog
advanc
keep
demand
grow
number
vaccin
manufactur
opt
work
new
welldefin
materi
purifi
protein
antigen
isol
natur
recombin
vector
specif
polysaccharid
oligosaccharid
protein
conjug
nucleic
acid
construct
advanc
strateg
divers
well
suit
work
bli
biosensor
technolog
due
label
free
realtim
aspect
technolog
incred
high
throughput
reliabl
bli
establish
technolog
alreadi
play
role
number
vaccin
studi
bli
technolog
use
kinet
affin
determin
well
specif
quantit
molecul
bound
tip
biosensor
provid
vast
array
applic
use
bli
assist
vaccin
research
develop
mani
way
includ
epitop
design
character
recognit
studi
pathogen
divers
distribut
antibodi
affin
develop
host
immun
respons
character
divers
distribut
nucleic
acid
molecular
pathogenhost
interact
studi
therapeut
clinic
studi
applic
still
discov
present
bli
technolog
alreadi
contribut
wide
rang
vaccin
studi
short
summari
enlist
differ
diseas
present
tabl
appendix
incred
divers
microb
abil
adapt
requir
constant
investig
molecular
interact
mode
action
diseas
bli
technolog
proven
work
multitud
strategi
involv
understand
diseas
mechan
action
possibl
modif
allow
improv
vaccin
potenc
follow
exampl
show
differ
applic
strategi
employ
bli
technolog
field
vaccin
studi
understand
interact
microb
host
big
step
improv
develop
new
vaccin
epitop
design
epitop
captur
approach
focu
microbi
molecular
structur
differ
epitop
may
differ
potenc
function
target
ultim
impact
vaccin
follow
exampl
show
strategi
employ
bli
contribut
understand
character
epitop
design
toward
vaccin
develop
improv
even
though
vaccin
small
pox
well
establish
one
first
vaccin
develop
ortholog
strain
concern
sinc
largescal
vaccin
effort
smallpox
end
gener
popul
may
longer
protect
orthopoxvirus
includ
monkeypox
viru
variou
strain
cowpox
virus
bli
technolog
use
tool
help
search
crossspeci
neutral
help
vaccin
design
develop
vaccinia
viru
wellorchestr
bli
strategi
summar
illustr
figur
author
studi
epitop
understand
protect
mechan
antibodi
antibodi
import
target
viral
neutral
residu
subject
singlealanin
substitut
use
sitedirect
mutagenesi
mutat
recombin
protein
immobil
onto
ninta
biosensor
via
ctermin
hexahistamin
tag
mab
use
analyt
measur
affin
constant
k
associ
rate
constant
k
dissoci
rate
constant
k
use
bind
model
author
compar
bind
kinet
wild
type
mab
result
found
bind
signific
differ
observ
wild
type
figur
tabl
signific
effect
bind
affin
observ
mab
studi
result
show
bind
protein
high
affin
singl
substitut
abolish
bind
prove
side
chain
essenti
bind
group
potent
neutral
antibodi
studi
show
bli
greatli
contribut
understand
function
studi
protein
involv
viral
recognit
lead
improv
vaccin
efficaci
futur
case
scenario
epitop
immobil
biosensor
first
mab
antibodi
solut
allow
bind
epitop
approach
use
sitedirect
mutagenesi
research
bli
assist
test
modifi
peptid
affin
bind
characterist
provid
realtim
function
answer
sitedirect
mutagenesi
gene
knockout
knockin
insert
delet
use
genet
manipul
recent
understand
mechan
involv
cluster
regularli
interspac
short
palindrom
repeat
crisprca
system
brought
great
advanc
enabl
precis
gene
modif
labelfre
biosensor
use
bridg
gap
gene
manipul
biolog
function
provid
refin
molecular
character
quantit
data
kinet
affin
inform
proteinprotein
interact
well
rnaprotein
dnaprotein
interact
figur
schemat
biolay
interferometri
bli
strategi
use
nickelcharg
trisnitrilotriacet
nta
biosensor
identif
viral
residu
activ
vaccinia
infect
sitedirect
mutagenesi
use
alter
residu
bli
use
test
affin
mab
tabl
show
bind
constant
result
versu
wildtyp
k
affin
constant
k
associ
constant
k
dissoci
constant
tabl
data
deriv
publish
data
author
consent
epitop
scaffold
make
use
comput
design
graft
epitop
interest
onto
heterolog
protein
scaffold
epitopefocus
vaccin
design
strategi
success
improv
vaccin
potenc
find
effect
vaccin
target
follow
exampl
bli
use
test
hcv
epitop
scaffold
affin
neutral
antibodi
contrari
smallpox
vaccin
hepat
c
viru
hcv
develop
prophylact
vaccin
hcv
hinder
due
great
divers
viral
structur
host
immun
respons
et
al
design
hcv
epitop
scaffold
antigen
site
glycoprotein
author
search
filter
potenti
scaffold
use
matrix
metaserv
method
compos
six
differ
databas
tmalign
f
tmalign
c
spalign
click
fast
mammoth
author
use
md
simul
studi
dynam
potenti
epitop
scaffold
solut
select
epitop
scaffold
histag
transient
express
cell
purifi
affin
test
bli
octet
instrument
multiscal
scaffold
promis
complex
pathogenhost
interact
structur
model
comput
design
test
experiment
activ
affin
use
differ
platform
bli
transform
theori
realiti
research
author
use
bli
instrumentan
octet
show
bind
affin
hcv
epitop
scaffold
neutral
antibodi
help
character
select
effici
scaffold
figur
case
scenario
antibodi
bound
preexist
igg
surfac
biosensor
epitop
scaffold
solut
allow
bind
secondari
antibodi
use
labelfre
biosensor
like
bli
spr
biochem
character
epitop
scaffold
contribut
sever
case
studi
report
influenza
rsv
hiv
biosensor
technolog
provid
affin
kinet
bind
inform
crucial
character
studi
like
spr
bli
provid
rate
constant
antibodi
bind
antigen
fit
model
function
bind
data
therefor
provid
affin
interact
epitop
bin
use
number
year
way
character
sort
librari
antibodi
bin
bind
distinct
epitop
specif
antigen
next
strategi
bli
demonstr
ideal
tool
expedit
epitop
bin
toward
vaccin
develop
case
focu
studi
antibioticresist
bacteria
caus
increas
public
health
concern
wang
et
al
explor
antibodybas
therapi
possibl
protect
klebsiella
pneumonia
bacteria
known
caus
nosocomi
infect
focus
protein
antigen
mrka
involv
biofilm
format
earli
onset
infect
studi
author
screen
character
epitop
pan
singlechain
variabl
fragment
scfv
antibodi
phage
librari
recombin
mrka
protein
start
coloni
narrow
four
clone
util
seri
methodolog
bind
specif
via
dual
express
vector
b
follow
bacteri
scfvfc
express
opsonophagocyt
kill
opk
vivo
activ
assess
c
scfv
sequenc
bli
epitop
bin
final
screen
clone
assess
bind
elisa
opk
affin
assay
bli
epitop
bin
result
four
clone
character
use
bli
technolog
character
four
remain
clone
author
use
biotinyl
antigen
captur
bli
streptavidin
biosensor
allow
protein
bind
antibodi
bin
two
remain
clone
show
similar
bind
profil
previous
character
antibodi
figur
show
diagram
one
clone
bli
approach
use
epitop
bin
use
number
year
way
character
sort
librari
antibodi
bin
bind
distinct
epitop
specif
antigen
next
strategi
bli
demonstr
ideal
tool
expedit
epitop
bin
toward
vaccin
develop
case
focu
studi
antibioticresist
bacteria
caus
increas
public
health
concern
wang
et
al
explor
antibodybas
therapi
possibl
protect
klebsiella
pneumonia
bacteria
known
caus
nosocomi
infect
focus
protein
antigen
mrka
involv
biofilm
format
earli
onset
infect
studi
author
screen
character
epitop
pan
singlechain
variabl
fragment
scfv
antibodi
phage
librari
recombin
mrka
protein
start
coloni
narrow
four
clone
util
seri
methodolog
bind
specif
via
dual
express
vector
b
follow
bacteri
scfvfc
express
opsonophagocyt
kill
opk
vivo
activ
assess
c
scfv
sequenc
bli
epitop
bin
final
screen
clone
assess
bind
elisa
opk
affin
assay
bli
epitop
bin
result
four
clone
character
use
bli
technolog
character
four
remain
clone
author
use
biotinyl
antigen
captur
bli
streptavidin
biosensor
allow
protein
bind
antibodi
bin
two
remain
clone
show
similar
bind
profil
previous
character
antibodi
figur
show
diagram
one
clone
bli
approach
use
figur
schemat
draw
show
intandem
epitop
bin
strategi
use
biofilm
format
protein
klebsiella
pneumonia
diagram
depict
biotinyl
mrka
antigen
immobil
streptavidin
sa
biosensor
expos
compet
antibodi
clone
interact
correspond
epitop
sensorgram
adapt
wang
et
al
permiss
show
bind
curv
differ
clone
buffer
clone
bind
site
avail
control
strategi
show
use
find
antimrka
antibodi
strong
affin
mrka
epitop
bli
octet
instrument
accept
complimentari
tool
epitop
bin
versatil
enabl
parallel
analysi
independ
analyteligand
pair
biosensor
platform
assist
differ
type
bin
assay
formatsintandem
premix
classic
sandwich
epitop
binningdu
labelfre
realtim
capabl
usual
classic
sandwich
intandem
format
use
crude
monoclon
antibodi
mab
supernat
premix
assay
use
purifi
mab
quantit
assay
bli
work
bin
format
crude
sampl
spr
spri
technolog
ideal
complex
sampl
caus
clog
blockag
microfluid
system
bli
also
offer
mani
advantag
tradit
technolog
elisa
epitop
bin
provid
realtim
inform
labelfre
experiment
design
elisa
hand
may
distort
molecul
conform
miss
inform
low
affin
antibodi
pair
limit
abil
troubleshoot
assay
due
limit
endpoint
labeldepend
technolog
exampl
describ
elisa
use
complementari
technolog
use
combin
bli
technolog
although
difficult
use
intandem
assay
elisa
tradit
use
sandwich
premix
assay
blideliv
epitop
cluster
use
intandem
strategi
develop
therapeut
antibodi
discoveri
studi
glucosedepend
insulinotrop
polypeptid
gip
receptor
purpos
possibl
diabet
obes
treatment
flexibl
bli
use
varieti
epitop
studi
mab
select
primari
screen
larg
librari
unpurifi
mab
express
crude
condit
media
kinet
screen
use
rtlf
biosensor
technolog
provid
rapid
select
potenti
candid
deliv
rapid
screen
mab
clone
bli
octet
technolog
htx
reliabl
measur
kinet
mabantigen
interact
wide
rang
bind
affin
data
gener
use
titrat
kinet
tk
singl
cycl
kinet
sck
assay
compar
use
bli
htx
biacor
spr
spri
biosensor
greater
advantag
bli
rtlf
biosensor
technolog
includ
reduc
handson
time
reduc
assay
time
higher
throughput
well
sampl
recoveri
end
experi
highthroughput
capabl
import
vaccin
develop
mani
way
epitop
screen
antibodi
screen
abil
test
multitud
target
funnel
toward
molecul
provid
highest
potenc
crucial
aspect
immunotherapeut
vaccin
develop
immunotherapeut
zmapp
tm
current
use
ebov
treatment
target
ebola
viru
surfac
glycoprotein
ebov
gp
howev
littl
known
actual
interact
mab
viru
understand
crucial
futur
develop
potent
effect
ebola
vaccin
attempt
better
understand
biolog
interact
viru
host
fortebio
octet
htx
system
conjunct
antihuman
igg
fc
ahq
biosensor
use
map
antigen
bind
specif
gp
glycoprotein
variant
popul
gpspecif
mab
monoclon
antibodi
isol
donor
survivor
zair
outbreak
figur
initi
highthroughput
screen
import
narrow
potent
target
bornholdt
et
al
abl
identifi
mab
target
interfac
gp
stalk
region
demonstr
great
progress
identif
mab
next
gener
ebov
immunotherapeut
purpos
possibl
diabet
obes
treatment
flexibl
bli
use
varieti
epitop
studi
mab
select
primari
screen
larg
librari
unpurifi
mab
express
crude
condit
media
kinet
screen
use
rtlf
biosensor
technolog
provid
rapid
select
potenti
candid
deliv
rapid
screen
mab
clone
bli
octet
technolog
htx
reliabl
measur
kinet
mabantigen
interact
wide
rang
bind
affin
data
gener
use
titrat
kinet
tk
singl
cycl
kinet
sck
assay
compar
use
bli
htx
biacor
spr
spri
biosensor
greater
advantag
bli
rtlf
biosensor
technolog
includ
reduc
handson
time
reduc
assay
time
higher
throughput
well
sampl
recoveri
end
experi
highthroughput
capabl
import
vaccin
develop
mani
way
epitop
screen
antibodi
screen
abil
test
multitud
target
funnel
toward
molecul
provid
highest
potenc
crucial
aspect
immunotherapeut
vaccin
develop
immunotherapeut
zmapp
tm
current
use
ebov
treatment
target
ebola
viru
surfac
glycoprotein
ebov
gp
howev
littl
known
actual
interact
mab
viru
understand
crucial
futur
develop
potent
effect
ebola
vaccin
attempt
better
understand
biolog
interact
viru
host
fortebio
octet
htx
system
conjunct
antihuman
igg
fc
ahq
biosensor
use
map
antigen
bind
specif
gp
glycoprotein
variant
popul
gpspecif
mab
monoclon
antibodi
isol
donor
survivor
zair
outbreak
figur
initi
highthroughput
screen
import
narrow
potent
target
bornholdt
et
al
abl
identifi
mab
target
interfac
gp
stalk
region
demonstr
great
progress
identif
mab
next
gener
ebov
immunotherapeut
approach
use
case
take
advantag
preexist
antihuman
igg
bound
ahq
biosensor
immobil
human
igg
larg
quantiti
bind
epitop
variant
solut
approach
show
versatil
bli
deliv
fast
high
approach
use
case
take
advantag
preexist
antihuman
igg
bound
ahq
biosensor
immobil
human
igg
larg
quantiti
bind
epitop
variant
solut
approach
show
versatil
bli
deliv
fast
highthroughput
result
allow
one
rapidli
make
kinet
analysi
bin
neutral
mab
competit
group
order
build
potent
immunotherapeut
reliabl
highthroughput
bli
platform
assist
multitud
vaccin
research
immunotherapeut
applic
recent
li
et
al
found
use
serolog
survey
seroepidemiolog
investig
identif
influenza
hemagglutinin
ha
subtyp
specif
antibodi
respons
influenza
viru
ha
glycoprotein
import
initi
stage
infect
respons
bind
viru
sialic
acid
present
host
cell
membran
serosurvey
util
ha
protein
evalu
estim
potenti
diseas
sever
tradit
serolog
survey
perform
hemagglutin
inhibit
hi
viru
microneutr
mn
assay
evalu
potenti
new
technolog
li
et
al
found
bli
present
high
sensit
expect
specif
human
sera
patient
expos
unexpos
heterolog
subtyp
influenza
ha
antibodi
design
manipul
serv
varieti
applic
medicin
scienc
past
decad
bispecif
antibodi
greatli
contribut
diagnost
therapeut
industri
includ
vaccin
research
develop
corrobor
advanc
bispecif
antibodi
research
bli
technolog
proven
assist
character
bispecif
antibodi
next
exampl
asokan
et
al
character
bispecif
antibodi
target
differ
epitop
envelop
protein
author
develop
four
differ
bispecif
antibodi
combin
demonstr
variou
level
neutral
increas
broad
potent
neutral
observ
bispecif
antibodi
contain
arm
bind
differ
region
hiv
viru
v
v
antigen
figur
throughput
result
allow
one
rapidli
make
kinet
analysi
bin
neutral
mab
competit
group
order
build
potent
immunotherapeut
reliabl
highthroughput
bli
platform
assist
multitud
vaccin
research
immunotherapeut
applic
recent
li
et
al
found
use
serolog
survey
seroepidemiolog
investig
identif
influenza
hemagglutinin
ha
subtyp
specif
antibodi
respons
influenza
viru
ha
glycoprotein
import
initi
stage
infect
respons
bind
viru
sialic
acid
present
host
cell
membran
serosurvey
util
ha
protein
evalu
estim
potenti
diseas
sever
tradit
serolog
survey
perform
hemagglutin
inhibit
hi
viru
microneutr
mn
assay
evalu
potenti
new
technolog
li
et
al
found
bli
present
high
sensit
expect
specif
human
sera
patient
expos
unexpos
heterolog
subtyp
influenza
ha
antibodi
design
manipul
serv
varieti
applic
medicin
scienc
past
decad
bispecif
antibodi
greatli
contribut
diagnost
therapeut
industri
includ
vaccin
research
develop
corrobor
advanc
bispecif
antibodi
research
bli
technolog
proven
assist
character
bispecif
antibodi
next
exampl
asokan
et
al
character
bispecif
antibodi
target
differ
epitop
envelop
protein
author
develop
four
differ
bispecif
antibodi
combin
demonstr
variou
level
neutral
increas
broad
potent
neutral
observ
bispecif
antibodi
contain
arm
bind
differ
region
hiv
viru
antigen
figur
diagram
show
bli
use
character
bispecif
antibodi
exampl
bispecif
antibodi
gener
harbor
fc
region
neutral
arm
hiv
viru
arm
bound
streptavidin
sa
biosensor
contain
target
antigen
second
arm
allow
bind
antigen
classic
sandwich
approach
sensorgram
reprint
permiss
show
bispecif
antibodi
red
line
versu
green
line
antibodi
ab
dark
blue
line
control
bind
profil
diagram
show
bli
use
character
bispecif
antibodi
exampl
bispecif
antibodi
gener
harbor
fc
region
neutral
arm
hiv
viru
arm
bound
streptavidin
sa
biosensor
contain
target
antigen
second
arm
allow
bind
v
v
antigen
classic
sandwich
approach
sensorgram
reprint
permiss
show
bispecif
antibodi
red
line
versu
green
line
antibodi
ab
dark
blue
line
control
bind
profil
case
scenario
one
arm
bispecif
antibodi
captur
antigen
bound
sa
biosensor
second
arm
bispecif
antibodi
bound
second
antigen
way
bispecif
antibodi
augment
neutral
abil
recogn
two
differ
site
hiv
viru
anoth
interest
exampl
usag
bli
use
viruslik
particl
vlp
chikungunya
viru
chikv
alphaviru
caus
debilit
arthrit
diseas
infect
million
peopl
worldwid
studi
underway
develop
vaccin
improv
therapeut
efficaci
viru
selvarajah
et
al
perform
experi
use
vlp
isol
panel
human
mab
author
use
octet
red
system
amin
reactiv
biosensor
show
bind
specif
one
mab
immobil
viral
envelop
glycoprotein
studi
author
use
human
mab
chikv
immobil
biosensor
use
purifi
chikv
vlp
bind
mab
figur
abil
bli
technolog
work
larg
particl
like
vlp
greatli
contribut
studi
vaccin
strategi
author
abl
captur
entir
chikungunya
vlp
biosensor
tip
studi
interact
mab
case
scenario
one
arm
bispecif
antibodi
captur
antigen
bound
sa
biosensor
second
arm
bispecif
antibodi
bound
second
antigen
way
bispecif
antibodi
augment
neutral
abil
recogn
two
differ
site
hiv
viru
anoth
interest
exampl
usag
bli
use
viruslik
particl
vlp
chikungunya
viru
chikv
alphaviru
caus
debilit
arthrit
diseas
infect
million
peopl
worldwid
studi
underway
develop
vaccin
improv
therapeut
efficaci
viru
selvarajah
et
al
perform
experi
use
vlp
isol
panel
human
mab
author
use
octet
red
system
amin
reactiv
biosensor
show
bind
specif
one
mab
immobil
viral
envelop
glycoprotein
studi
author
use
human
mab
chikv
immobil
biosensor
use
purifi
chikv
vlp
bind
mab
figur
abil
bli
technolog
work
larg
particl
like
vlp
greatli
contribut
studi
vaccin
strategi
author
abl
captur
entir
chikungunya
vlp
biosensor
tip
studi
interact
mab
figur
schemat
draw
show
bli
strategi
captur
viruslik
particl
vlp
mab
captur
surfac
biosensor
chikungunya
chikv
vlp
allow
bind
mab
sensorgram
show
bind
chikv
vlp
biosensor
comparison
buffer
control
note
sensorgram
reprint
author
permiss
brilliant
exampl
whole
influenza
viru
captur
onto
streptavidin
sa
biosensor
mean
biotinyl
sialic
acid
attempt
better
understand
human
avian
viru
divers
receptor
bind
interact
author
bound
biotinyl
sialyl
lactosamin
polym
sa
biosensor
allow
virus
bind
polym
figur
author
calcul
rel
amount
viru
bound
biosensor
differ
sugar
load
normal
viru
bind
respons
curv
relat
fraction
satur
sensor
surfac
data
fit
improv
variant
hill
equat
fraction
satur
sensor
surfac
relat
appar
equilibrium
dissoci
constant
viru
bind
kd
viru
calcul
function
rel
sugar
load
valu
rang
dipandread
capabl
bli
tend
favor
whole
viru
vlp
applic
spr
instrument
bli
prone
sprspecif
limit
spr
specif
figur
schemat
draw
show
bli
strategi
captur
viruslik
particl
vlp
mab
captur
surfac
biosensor
chikungunya
chikv
vlp
allow
bind
mab
sensorgram
show
bind
chikv
vlp
biosensor
comparison
buffer
control
note
sensorgram
reprint
author
permiss
brilliant
exampl
whole
influenza
viru
captur
onto
streptavidin
sa
biosensor
mean
biotinyl
sialic
acid
attempt
better
understand
human
avian
viru
divers
receptor
bind
interact
author
bound
biotinyl
sialyl
lactosamin
polym
sa
biosensor
allow
virus
bind
polym
figur
author
calcul
rel
amount
viru
bound
biosensor
differ
sugar
load
normal
viru
bind
respons
curv
relat
fraction
satur
sensor
surfac
data
fit
improv
variant
hill
equat
fraction
satur
sensor
surfac
relat
appar
equilibrium
dissoci
constant
viru
bind
k
viru
calcul
function
rel
sugar
load
valu
rang
dipandread
capabl
bli
tend
favor
whole
viru
vlp
applic
spr
instrument
bli
prone
sprspecif
limit
spr
specificlimit
includ
masstransport
limit
artifact
caus
chemic
microheterogen
surfac
biosensor
usual
compar
spr
technolog
bli
intrins
characterist
tend
favor
multipl
applic
mostli
due
abil
dip
dispos
biosensor
onto
solut
contain
sampl
reagent
tend
prevent
artifact
deposit
biosensor
prevent
fluidic
limit
immobil
virus
vlp
realtim
labelfre
kinet
quantit
character
unlock
mani
potenti
vaccin
studi
limit
includ
masstransport
limit
artifact
caus
chemic
microheterogen
surfac
biosensor
usual
compar
spr
technolog
bli
intrins
characterist
tend
favor
multipl
applic
mostli
due
abil
dip
dispos
biosensor
onto
solut
contain
sampl
reagent
tend
prevent
artifact
deposit
biosensor
prevent
fluidic
limit
immobil
virus
vlp
realtim
labelfre
kinet
quantit
character
unlock
mani
potenti
vaccin
studi
use
nucleic
acid
vaccin
develop
strategi
grown
past
year
novel
approach
proven
efficaci
continu
flourish
next
exampl
show
use
genom
rna
bind
affin
eukaryot
translat
elong
factor
involv
replic
li
et
al
use
biotinyl
rt
luciferas
rna
individu
test
bind
affin
figur
author
found
rna
strongli
bound
rt
rna
show
week
bind
luciferas
rna
bind
similarli
bind
shown
author
use
translat
factor
indic
specif
rna
figur
schemat
bli
approach
use
sa
biosensor
bind
biotinyl
rna
allow
bind
translat
factor
hivhost
interact
sensorgram
show
bind
factor
versu
control
reprint
author
permiss
use
nucleic
acid
vaccin
develop
strategi
grown
past
year
novel
approach
proven
efficaci
continu
flourish
next
exampl
show
use
genom
rna
bind
affin
eukaryot
translat
elong
factor
involv
replic
li
et
al
use
biotinyl
utr
rt
luciferas
rna
individu
test
bind
affin
figur
author
found
utr
rna
strongli
bound
rt
rna
show
week
bind
luciferas
rna
bind
similarli
bind
shown
author
use
translat
factor
indic
specif
utr
rna
limit
includ
masstransport
limit
artifact
caus
chemic
microheterogen
surfac
biosensor
usual
compar
spr
technolog
bli
intrins
characterist
tend
favor
multipl
applic
mostli
due
abil
dip
dispos
biosensor
onto
solut
contain
sampl
reagent
tend
prevent
artifact
deposit
biosensor
prevent
fluidic
limit
immobil
virus
vlp
realtim
labelfre
kinet
quantit
character
unlock
mani
potenti
vaccin
studi
use
nucleic
acid
vaccin
develop
strategi
grown
past
year
novel
approach
proven
efficaci
continu
flourish
next
exampl
show
use
genom
rna
bind
affin
eukaryot
translat
elong
factor
involv
replic
li
et
al
use
biotinyl
rt
luciferas
rna
individu
test
bind
affin
figur
author
found
rna
strongli
bound
rt
rna
show
week
bind
luciferas
rna
bind
similarli
bind
shown
author
use
translat
factor
indic
specif
rna
figur
schemat
bli
approach
use
sa
biosensor
bind
biotinyl
rna
allow
bind
translat
factor
hivhost
interact
sensorgram
show
bind
factor
versu
control
reprint
author
permiss
figur
schemat
bli
approach
use
sa
biosensor
bind
biotinyl
utr
rna
allow
bind
translat
factor
hivhost
interact
sensorgram
show
bind
utr
factor
versu
control
reprint
author
permiss
approach
show
use
bli
studi
involv
nucleic
acid
quit
promis
understand
viralhost
interact
vaccin
develop
bli
platform
attract
applic
lower
sampl
volum
requir
nondestruct
nondilut
natur
assay
biosensor
tip
regener
part
allow
multius
biosensor
tip
nucleic
acid
applic
bli
ad
advantag
detect
mechanist
structur
nucleic
acid
chang
upon
bind
exampl
bruno
notic
use
long
base
pair
aptam
bind
peptid
base
biomark
aptam
contract
result
smaller
molecul
exhibit
neg
respons
signal
upon
bind
peptid
friedman
et
al
found
bli
invalu
character
aptam
pool
enrich
tradit
access
radiolabel
aptam
either
atp
p
vitro
transcript
atp
p
end
label
author
found
radiolabel
disrupt
aptam
function
rtlf
bli
biosensor
technolog
provid
fast
highthroughput
reliabl
affin
inform
could
test
parallel
comparison
sampl
differ
select
round
addit
radiolabel
cumbersom
techniqu
requir
care
manipul
extra
wast
dispos
cost
aptam
use
vaccin
immunotherapeut
initi
highli
specif
aptam
bind
viral
protein
inhibit
block
fusion
penetr
replic
exampl
clearli
demonstr
import
understand
bind
affin
mab
specif
host
respons
epitop
specif
screen
toward
develop
vaccin
thu
surg
bli
emerg
method
field
vaccin
immunotherapeut
attract
lab
worldwid
summon
new
applic
possibl
bli
technolog
greatli
assist
vaccin
research
develop
recent
year
variou
labelfre
bli
platform
biosensor
possibl
obtain
detail
inform
bind
kinet
specificityaffin
immun
respons
epitop
map
vaccin
titer
concentr
make
bli
power
techniqu
adopt
laboratori
involv
develop
product
vaccin
scientist
tri
prevent
remedi
pathogen
attack
ultim
goal
protect
popul
